Construction and screening of attenuated ΔphoP/Q Salmonella typhimurium vectored plague vaccine candidates

Donata R. Sizemore, Elizabeth A. Warner, Julie A. Lawrence, Lawrence J. Thomas, Kenneth L. Roland, Kevin P. Killeen

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Preclinical studies evaluating plague vaccine candidates have demonstrated that the F1 and V protein antigens of Yersinia pestis confer protection against challenge from virulent strains. Live-attenuated ΔphoP/Q Salmonella typhimurium recombinants were constructed expressing either F1, V antigens, F1 and V antigens, or a F1-V fusion from Asd + balanced-lethal plasmids. To improve antigen Landes delivery, genes encoding plague antigens were modified in order to localize antigens to specific bacterial cellular compartments which include cytoplasmic, outer membrane, or secreted. Candidate vaccine strains were evaluated for growth characteristics, full-length lipopolysaccharide (LPS), plasmid stability, and antigen expression in vitro. Plague vaccine candidate strains with favorable in vitro profiles were evaluated in murine or rabbit preclinical oral immunogenicity studies. Attenuated S. typhimurium strains expressing cytoplasmically localized F1-V and V antigen antigens were more immunogenic than strains that secreted or localized plague antigens to the outer membrane. In particular, S. typhimurium M020 and M023, which express Asd +- plasmid derived soluble F1-V and soluble V antigen, respectively, at high levels in the bacterial cell cytoplasm were found to induce the highest levels of plague-specific serum antibodies. To further evaluate balanced-lethal plasmid retention capacity, ΔphoP/Q S. typhimurium PurB + and GlnA + balanced-lethal plasmid systems harboring F1-V were compared with M020 in vitro and in BALB/c mice in a immunogenicity study. Although there was no detectable difference in plague antigen expression in vitro, S. typhimurium M020 was the most immunogenic plague antigen vector strain evaluated, inducing high-titer serum IgG antibodies specific against F1, V and F1-V.

Original languageEnglish (US)
Pages (from-to)362-374
Number of pages13
JournalHuman Vaccines and Immunotherapeutics
Volume8
Issue number3
DOIs
StatePublished - Mar 2012

Fingerprint

Plague Vaccine
Salmonella typhimurium
Antigens
Plague
Plasmids
Yersinia pestis
Antibodies

Keywords

  • F1-V
  • Immunogenicity
  • Plague
  • Salmonella typhimurium
  • Vaccine

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Pharmacology

Cite this

Sizemore, D. R., Warner, E. A., Lawrence, J. A., Thomas, L. J., Roland, K. L., & Killeen, K. P. (2012). Construction and screening of attenuated ΔphoP/Q Salmonella typhimurium vectored plague vaccine candidates. Human Vaccines and Immunotherapeutics, 8(3), 362-374. https://doi.org/10.4161/hv.8.3.18670

Construction and screening of attenuated ΔphoP/Q Salmonella typhimurium vectored plague vaccine candidates. / Sizemore, Donata R.; Warner, Elizabeth A.; Lawrence, Julie A.; Thomas, Lawrence J.; Roland, Kenneth L.; Killeen, Kevin P.

In: Human Vaccines and Immunotherapeutics, Vol. 8, No. 3, 03.2012, p. 362-374.

Research output: Contribution to journalArticle

Sizemore, Donata R. ; Warner, Elizabeth A. ; Lawrence, Julie A. ; Thomas, Lawrence J. ; Roland, Kenneth L. ; Killeen, Kevin P. / Construction and screening of attenuated ΔphoP/Q Salmonella typhimurium vectored plague vaccine candidates. In: Human Vaccines and Immunotherapeutics. 2012 ; Vol. 8, No. 3. pp. 362-374.
@article{22a58cb397d24d7fb390f9bea28dc3d5,
title = "Construction and screening of attenuated ΔphoP/Q Salmonella typhimurium vectored plague vaccine candidates",
abstract = "Preclinical studies evaluating plague vaccine candidates have demonstrated that the F1 and V protein antigens of Yersinia pestis confer protection against challenge from virulent strains. Live-attenuated ΔphoP/Q Salmonella typhimurium recombinants were constructed expressing either F1, V antigens, F1 and V antigens, or a F1-V fusion from Asd + balanced-lethal plasmids. To improve antigen Landes delivery, genes encoding plague antigens were modified in order to localize antigens to specific bacterial cellular compartments which include cytoplasmic, outer membrane, or secreted. Candidate vaccine strains were evaluated for growth characteristics, full-length lipopolysaccharide (LPS), plasmid stability, and antigen expression in vitro. Plague vaccine candidate strains with favorable in vitro profiles were evaluated in murine or rabbit preclinical oral immunogenicity studies. Attenuated S. typhimurium strains expressing cytoplasmically localized F1-V and V antigen antigens were more immunogenic than strains that secreted or localized plague antigens to the outer membrane. In particular, S. typhimurium M020 and M023, which express Asd +- plasmid derived soluble F1-V and soluble V antigen, respectively, at high levels in the bacterial cell cytoplasm were found to induce the highest levels of plague-specific serum antibodies. To further evaluate balanced-lethal plasmid retention capacity, ΔphoP/Q S. typhimurium PurB + and GlnA + balanced-lethal plasmid systems harboring F1-V were compared with M020 in vitro and in BALB/c mice in a immunogenicity study. Although there was no detectable difference in plague antigen expression in vitro, S. typhimurium M020 was the most immunogenic plague antigen vector strain evaluated, inducing high-titer serum IgG antibodies specific against F1, V and F1-V.",
keywords = "F1-V, Immunogenicity, Plague, Salmonella typhimurium, Vaccine",
author = "Sizemore, {Donata R.} and Warner, {Elizabeth A.} and Lawrence, {Julie A.} and Thomas, {Lawrence J.} and Roland, {Kenneth L.} and Killeen, {Kevin P.}",
year = "2012",
month = "3",
doi = "10.4161/hv.8.3.18670",
language = "English (US)",
volume = "8",
pages = "362--374",
journal = "Human Vaccines and Immunotherapeutics",
issn = "2164-5515",
publisher = "Landes Bioscience",
number = "3",

}

TY - JOUR

T1 - Construction and screening of attenuated ΔphoP/Q Salmonella typhimurium vectored plague vaccine candidates

AU - Sizemore, Donata R.

AU - Warner, Elizabeth A.

AU - Lawrence, Julie A.

AU - Thomas, Lawrence J.

AU - Roland, Kenneth L.

AU - Killeen, Kevin P.

PY - 2012/3

Y1 - 2012/3

N2 - Preclinical studies evaluating plague vaccine candidates have demonstrated that the F1 and V protein antigens of Yersinia pestis confer protection against challenge from virulent strains. Live-attenuated ΔphoP/Q Salmonella typhimurium recombinants were constructed expressing either F1, V antigens, F1 and V antigens, or a F1-V fusion from Asd + balanced-lethal plasmids. To improve antigen Landes delivery, genes encoding plague antigens were modified in order to localize antigens to specific bacterial cellular compartments which include cytoplasmic, outer membrane, or secreted. Candidate vaccine strains were evaluated for growth characteristics, full-length lipopolysaccharide (LPS), plasmid stability, and antigen expression in vitro. Plague vaccine candidate strains with favorable in vitro profiles were evaluated in murine or rabbit preclinical oral immunogenicity studies. Attenuated S. typhimurium strains expressing cytoplasmically localized F1-V and V antigen antigens were more immunogenic than strains that secreted or localized plague antigens to the outer membrane. In particular, S. typhimurium M020 and M023, which express Asd +- plasmid derived soluble F1-V and soluble V antigen, respectively, at high levels in the bacterial cell cytoplasm were found to induce the highest levels of plague-specific serum antibodies. To further evaluate balanced-lethal plasmid retention capacity, ΔphoP/Q S. typhimurium PurB + and GlnA + balanced-lethal plasmid systems harboring F1-V were compared with M020 in vitro and in BALB/c mice in a immunogenicity study. Although there was no detectable difference in plague antigen expression in vitro, S. typhimurium M020 was the most immunogenic plague antigen vector strain evaluated, inducing high-titer serum IgG antibodies specific against F1, V and F1-V.

AB - Preclinical studies evaluating plague vaccine candidates have demonstrated that the F1 and V protein antigens of Yersinia pestis confer protection against challenge from virulent strains. Live-attenuated ΔphoP/Q Salmonella typhimurium recombinants were constructed expressing either F1, V antigens, F1 and V antigens, or a F1-V fusion from Asd + balanced-lethal plasmids. To improve antigen Landes delivery, genes encoding plague antigens were modified in order to localize antigens to specific bacterial cellular compartments which include cytoplasmic, outer membrane, or secreted. Candidate vaccine strains were evaluated for growth characteristics, full-length lipopolysaccharide (LPS), plasmid stability, and antigen expression in vitro. Plague vaccine candidate strains with favorable in vitro profiles were evaluated in murine or rabbit preclinical oral immunogenicity studies. Attenuated S. typhimurium strains expressing cytoplasmically localized F1-V and V antigen antigens were more immunogenic than strains that secreted or localized plague antigens to the outer membrane. In particular, S. typhimurium M020 and M023, which express Asd +- plasmid derived soluble F1-V and soluble V antigen, respectively, at high levels in the bacterial cell cytoplasm were found to induce the highest levels of plague-specific serum antibodies. To further evaluate balanced-lethal plasmid retention capacity, ΔphoP/Q S. typhimurium PurB + and GlnA + balanced-lethal plasmid systems harboring F1-V were compared with M020 in vitro and in BALB/c mice in a immunogenicity study. Although there was no detectable difference in plague antigen expression in vitro, S. typhimurium M020 was the most immunogenic plague antigen vector strain evaluated, inducing high-titer serum IgG antibodies specific against F1, V and F1-V.

KW - F1-V

KW - Immunogenicity

KW - Plague

KW - Salmonella typhimurium

KW - Vaccine

UR - http://www.scopus.com/inward/record.url?scp=84860381502&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84860381502&partnerID=8YFLogxK

U2 - 10.4161/hv.8.3.18670

DO - 10.4161/hv.8.3.18670

M3 - Article

C2 - 22327496

AN - SCOPUS:84860381502

VL - 8

SP - 362

EP - 374

JO - Human Vaccines and Immunotherapeutics

JF - Human Vaccines and Immunotherapeutics

SN - 2164-5515

IS - 3

ER -